medRxiv Preprint Server
May 23, 2026
Lisa Maria Jöbstl, Bente Lubahn, Ebru Kaya et al.
preprint
Background While growing enthusiasm for the therapeutic potential of classic psychedelics has led to a rise in non-clinical use, attention to persisting adverse effects has emerged with delay. A subset of individuals reports persisting complications such as hallucinogen persisting perception disorder (HPPD), depersonalization/derealization disorder (DDD), anxiety and depression. Yet few medical...
Journal of Psychopharmacology
March 31, 2025
Tomislav Majić, Timo Torsten Schmidt, Anna Gröticke et al.
4 citations
Background: Classic psychedelics such as psilocybin and lysergic acid diethylamide are anecdotally associated with the phenomenon of “psychedelic afterglow,” a set of predominantly pleasant, temporary psychological effects reported after the acute effects have subsided. Since post-acute effects are crucial for the therapeutic use of psychedelics, an instrument to systematically assess subacute...
Scientific Reports
December 31, 2024
Georg Leistenschneider, Tomislav Majić, Simon Reiche et al.
3 citations
Abstract Classic psychedelics like LSD and psilocybin are showing promising effects in treating certain psychiatric disorders. Despite their low toxicity and lack of an addictive potential, in some individuals, psychedelics can be associated with persisting psychological harms. Hallucinogen Persisting Perception Disorder (HPPD) is one of those complications, a rare disorder characterized by...
Scientific Reports
June 26, 2024
Lukas A Basedow, Tomislav Majić, Nicklas Jakob Hafiz et al.
13 citations
Classic psychedelics and MDMA have a colorful history of recreational use, and both have recently been re-evaluated as tools for the treatment of psychiatric disorders. Several studies have been carried out to assess potential long-term effects of a regular use on cognition, delivering distinct results for psychedelics and MDMA. However, to date knowledge is scarce on cognitive performance...
Frontiers in Pharmacology
September 16, 2021
Lukas A Basedow, Thomas Riemer, Simon Reiche et al.
16 citations
Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at 5-HT 2a receptors. Besides the ability of these substances to facilitate profoundly altered states of consciousness, persisting psychological effects have been reported after single administrations, which outlast the acute psychedelic effects. In...